Cancer-Initiating Cell Biomarker Assay for Triple-Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Basal-like breast tumors, or triple-negative breast cancers, are aggressive and refractory to chemotherapy and endocrine therapy, with a poor prognosis due to early relapse and rapid resistance to treatment, necessitating new diagnostic and therapeutic approaches.
Innovation Solution
Identification of novel malignancy-associated response signatures and assays using a genome-wide siRNA lethality screen in breast epithelial cells, which reveal specific biomarkers and pathways for classifying cancer-initiating cells and targeting therapeutic agents like proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional chemotherapy and endocrine therapy are used to treat basal-like breast tumors, then initial treatment response is achieved, but rapid resistance develops and early relapse occurs
Solution Approach 1:
The patent segments the tumor population by identifying and targeting cancer-initiating cells (CICs) with CD44+CD24- phenotype separately from bulk tumor cells. This segmentation allows for targeted therapy against the specific cell population responsible for treatment resistance and relapse, rather than treating all tumor cells uniformly with conventional chemotherapy.
Solution Approach 2:
The patent changes the therapeutic parameter from non-specific cytotoxic agents to targeted inhibitors that specifically affect CICs. By identifying molecular markers (CD44, CD24) and downstream signaling pathways unique to CICs, the treatment parameter shifts from bulk cell killing to precision targeting, thereby extending durable response without accelerating resistance.
2Productivity
If aggressive chemotherapy is administered to treat basal-like breast tumors, then tumor growth is initially suppressed, but early relapse within five years occurs due to resistance
Solution Approach 1:
The patent performs preliminary identification and characterization of cancer-initiating cells before treatment initiation. By pre-identifying CICs through CD44+CD24- marker expression and understanding their unique molecular profile, the treatment plan can be预先 designed to specifically target these cells, preventing their survival and subsequent relapse that occurs with conventional therapy.
Solution Approach 2:
The patent introduces molecular markers (CD44, CD24) and pathway-specific inhibitors as intermediaries between the therapeutic agent and the tumor cells. These intermediaries enable selective recognition and targeting of CICs, allowing tumor control to be achieved through precise molecular mediation rather than non-specific cytotoxicity, thereby extending relapse-free survival.
3Ease of manufacture
If conventional therapy approaches are used, then standard treatment protocols are followed, but refractory tumors remain untreated due to lack of effective options
Solution Approach 1:
The patent develops a universal diagnostic framework based on CD44+CD24- marker expression and malignancy-associated response signatures that can identify CICs across different basal-like breast tumor cases. This universal approach enables standardized identification and targeting of CICs regardless of specific patient characteristics, making the therapy broadly applicable and available while simultaneously providing adaptable treatment options through pathway-specific inhibitors.
Data Source
AI summary
Described herein are novel malignancy associated gene signature biomarkers, and assays and methods thereof, to classify prognosis or malignant potential of a cancer and identify cancer-initiating cells. The malignancy associated gene signature biomarkers, assays and methods described herein provide, in part, new methodologies to screen for novel drugs for treating cancers and tumors, such as, for example, triple-negative breast tumors. Using the assays and methods described herein proteasome inhibitors, histone deacetylase inhibitors, and glycolysis inhibitors, were identified as being highly effective in altering gene expression signatures specifically in malignant or cancer-initiating cells.